Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: emil who wrote (1308)	12/1/1997 2:25:00 PM
From: tom jones	Read Replies (2) \| Respond to of 4676

To all: Isis 5132 phase I results. This is from the news of Isis 5132 going to phase II. Two Phase I studies of ISIS 5132/CGP69846A were conducted on patients with a wide variety of cancers. Results from the phase I studies demonstrated that the drug was well tolerated and that several patients experienced disease stabilization. Of the 13 patients with colon cancer enrolled in the studies, one experienced a decrease in CEA, a colon cancer marker, with no growth in tumor for approximately seven months. Another patient, with renal cancer, has experienced disease stabilization for about 6 months and continues to be on study. In the second study, one patient with renal cancer has experienced disease stabilization for 9 months while another patient, with ovarian cancer, experienced disease stabilization and a 95% drop in CA-125, an ovarian cancer marker, and continues to be on study after 6 cycles. I know this is just phase I and one is not to expect results but why is just one person responding per study? Is this the person that was getting the high dose? Can we find out what happened to the other people? Comments? Tom